Concepedia

Publication | Open Access

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

DOIFull Paper Access

252

Citations

16

References

2010

Year

Jennie H. Best, Byron J. Hoogwerf, William H. Herman, Elise M. Pelletier, Daniel B. Smith, Madé Wenten, Mohamed Hussein
Diabetes Care

Abstract

Exenatide twice-daily treatment was associated with a lower risk of CVD events and hospitalizations than treatment with other glucose-lowering therapies.

References

YearCitations

Page 1